Skip to main content

8-K

Niagen Bioscience, Inc. (NAGE)

8-K 2020-07-08 For: 2020-07-06
View Original
Added on April 10, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

____________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 6, 2020

CHROMADEX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 001-37752 26-2940963
(State<br>or other jurisdiction of incorporation) (Commission<br>File Number) (IRS<br>Employer Identification No.)

10900 Wilshire Blvd. Suite 600, Los Angeles, California 90024

(Address of principal executive offices, including zip code)

(310) 388-6706

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title<br>of each class Trading<br>Symbol(s) Name of<br>each exchange on which registered
Common<br>Stock, par value $0.001 per share CDXC The<br>Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

ChromaDex Corporation (the “Company” or “ChromaDex”) recently became aware that, due to an administrative error, certain of the Company’s previously filed Annual Reports on Form 10-K, including the Annual Report on Form 10-K for the year ended December 31, 2019, as amended, contained the wrong filing, issued and/or expiration dates with respect to certain of the Company’s owned and licensed patents. The following table sets forth the Company’s existing owned and licensed patents with such filing, issued and/or expiration dates as corrected:

Patent Number Title Filing Date Issued Date Expires Licensor
7,205,284 Potent<br>immunostimulants from microalgae 7/10/2001 4/17/2007 3/9/2022 Licensed<br>from University of Mississippi
7,776,326 Methods<br>and compositions for treating neuropathies 6/3/2005 8/17/2010 6/24/2026 Licensed<br>from Washington University
7,846,452 Potent<br>immunostimulatory extracts from microalgae 7/28/2005 12/7/2010 7/28/2025 Licensed<br>from University of Mississippi
8,106,184 Nicotinyl<br>Riboside Compositions and Methods of Use 11/17/2006 1/31/2012 9/20/2027 Licensed<br>from Cornell University
8,114,626 Yeast<br>strain and method for using the same to produce Nicotinamide<br>Riboside 3/26/2009 2/14/2012 1/5/2026 Licensed<br>from Dartmouth College
8,133,917 Pterostilbene<br>as an agonist for the peroxisome proliferator-activated receptor<br>alpha isoform 10/25/2010 3/13/2012 8/18/2025 Licensed<br>from the University of Mississippi and U.S. Department of<br>Agriculture
8,197,807 Nicotinamide<br>Riboside Kinase compositions and Methods for using the<br>same 4/20/2006 6/12/2012 11/19/2026 Licensed<br>from Dartmouth College
8,252,845 Pterostilbene<br>as an agonist for the peroxisome proliferator-activated receptor<br>alpha isoform 2/1/2012 8/28/2012 8/18/2025 Licensed<br>from the University of Mississippi and U.S. Department of<br>Agriculture
8,318,807 Pterostilbene<br>Caffeine Co-Crystal Forms 7/30/2010 11/27/2012 7/21/2031 Licensed<br>from Laurus Labs Private Limited
8,383,086 Nicotinamide<br>Riboside Kinase compositions and Methods for using the<br>same 4/12/2012 2/26/2013 4/20/2026 Licensed<br>from Dartmouth College
8,399,712 Pterostilbene<br>cocrystals 7/30/2010 3/19/2013 8/10/2031 Licensed<br>from Laurus Labs Private Limited
--- --- --- --- --- ---
8,524,782 Key<br>intermediate for the preparation of Stilbenes, solid forms of<br>Pterostilbene, and methods for making the same 1/21/2011 9/3/2013 2/1/2030 Licensed<br>from Laurus Labs Private Limited
8,809,400 Method<br>to Ameliorate Oxidative Stress and Improve Working Memory Via<br>Pterostilbene Administration 8/8/2011 8/19/2014 10/2/2028 Licensed<br>from the University of Mississippi and U.S. Department of<br>Agriculture
8,841,350 Method<br>for treating non-melanoma skin cancer by inducing<br>UDP-Glucuronosyltransferase activity using<br>pterostilbene 5/8/2012 9/23/2014 5/8/2032 Co-owned<br>by ChromaDex and University of California
8,889,126 Methods<br>and compositions for treating neuropathies 5/28/2010 11/18/2014 6/3/2025 Licensed<br>from Washington University
9,000,147 Nicotyl<br>riboside compositions and methods of use 1/17/2012 4/7/2015 11/17/2026 Licensed<br>from Cornell University
9,028,887 Method<br>improve spatial memory via pterostilbene<br>administration 5/22/2014 5/12/2015 6/10/2028 Licensed<br>from the University of Mississippi and U.S. Department of<br>Agriculture
9,295,688 Methods<br>and compositions for treating neuropathies 10/10/2014 3/29/2016 6/3/2025 Licensed<br>from Washington University
9,321,797 Nicotyl<br>riboside compositions and methods of use 11/17/2014 4/26/2016 11/17/2026 Licensed<br>from Cornell University
9,439,875 Anxiolytic<br>effect of pterostilbene 5/11/2011 9/13/2016 12/11/2031 Licensed<br>from the University of Mississippi and U.S. Department of<br>Agriculture
9,975,915 Crystalline<br>forms of nicotinoyl ribosides, modified derivatives thereof, and<br>phosphorylated analogs thereof, and methods of preparation<br>thereof 11/10/2017 5/22/2018 11/10/2037 Co-owned<br>by ChromaDex and The Queen’s University of<br>Belfast
10,000,519 Methods of Preparing Nicotinamide Riboside and Derivatives<br>Thereof 7/24/2014 6/19/2018 7/24/2034 Licensed from The Queen’s University of<br>Belfast
10,000,520 B-vitamin<br>and amino acid conjugates ofnicotinoyl ribosides and reduced<br>nicotinoyl ribosides, derivatives thereof, and methods of<br>preparation thereof 3/16/2017 6/19/2018 3/16/2037 Co-owned<br>by ChromaDex and The Queen’s University of<br>Belfast
10,183,036 Use of nicotinic acid riboside or nicotinamide riboside<br>derivatives, and reduced derivatives thereof, as NAD+ increasing<br>precursors 4/20/2017 1/22/2019 4/20/2037 Owned by ChromaDex
10,280,190 Nicotinic acid riboside or nicotinamide riboside compositions,<br>reduced derivatives thereof, and the use thereof to enhance skin<br>permeation in treating skin conditions 3/16/2016 5/7/2019 5/31/2036 Co-owned by ChromaDex and The Queen’s University of<br>Belfast
10,688,118 Nicotinamide riboside compositions for topical use in treating skin<br>conditions 10/30/2014 6/23/2020 4/6/2035 Owned by ChromaDex
10,689,411 Efficient and scalable syntheses of nicotinoyl ribosides and<br>reduced nicotinoyl ribosides, modified derivatives thereof,<br>phosphorylated analogs thereof, adenylyl dinucleotide conjugates<br>thereof, and novel crystalline forms<br>thereof 11/10/2017 6/23/2020 11/10/2037 Co-owned by ChromaDex and The Queen’s University of<br>Belfast

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHROMADEX CORPORATION
Dated:<br>July 8, 2020
By: /s/<br>Kevin M.<br>Farr
Name:<br>Kevin M. Farr
Chief<br>Financial Officer